Effects of glucocorticoids on interstitial glucose concentrations in individuals with hematologic cancer and without known diagnosis of diabetes: a pilot study

Imagem de Miniatura
Arquivos
art_TOYOSHIMA_Effects_of_glucocorticoids_on_interstitial_glucose_concentrations_in_2022.PDF (407.64 KB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2022
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
INST ISRAELITA ENSINO & PESQUISA ALBERT EINSTEIN
Autores
Citação
EINSTEIN-SAO PAULO, v.20, article ID eAO8031, 9p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: To analyze interstitial glucose behavior during glucocorticoid use in non-diabetic patients receiving chemotherapy for hematologic malignancies. Methods: Prospective pilot study carried out to assess interstitial glucose levels in 15 non-diabetic individuals with hematologic malignancies who received glucocorticoids in combination with chemotherapy. The FreeStyle Libre flash monitoring system (Abbott Diabetes Care) was used for up to 14 days to measure interstitial glucose. Results: Median age and body mass index were 53 (42-61) years and 25 (23-28) kg/m(2) respectively. Interstitial glucose levels >180mg/dL lasting at least one hour were detected in 60% of participants. Interstitial glucose profile parameters (median and peak interstitial glucose levels and percentage of time during which interstitial glucose levels were >180mg/dL) were significantly (p<0.01) higher during glucocorticoid use (115mg/dL, 218mg/dL and 10% respectively) than after glucocorticoid discontinuation (97mg/dL, 137mg/dL and 0% respectively). Mean interstitial glucose levels increased in the afternoon and at night during glucocorticoid use. Conclusion: This pilot study was the first to evaluate interstitial glucose levels in non-diabetic individuals using glucocorticoids in treatment of hematologic cancer. Glucocorticoid use during chemotherapy significantly increases interstitial glucose levels in these patients.
Palavras-chave
Blood glucose, Glucose, Hematologic neoplasms, Lymphoma, Hyperglycemia, Glucocorticoids, Diabetes mellitus, Drug therapy
URI
https://observatorio.fm.usp.br/handle/OPI/50383
Referências
  1. Aberer F, 2021, J CLIN MED, V10, DOI 10.3390/jcm10102154
  2. Bailey T, 2015, DIABETES TECHNOL THE, V17, P787, DOI 10.1089/dia.2014.0378
  3. Beaupere C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020623
  4. Bostrom BC, 2003, BLOOD, V101, P3809, DOI 10.1182/blood-2002-08-2454
  5. Brunello A, 2011, AM J CLIN ONCOL-CANC, V34, P292, DOI 10.1097/COC.0b013e3181e1d0c0
  6. Burt MG, 2011, J CLIN ENDOCR METAB, V96, P1789, DOI 10.1210/jc.2010-2729
  7. Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194
  8. Chevalier S, 2014, APPL PHYSIOL NUTR ME, V39, P643, DOI 10.1139/apnm-2013-0369
  9. Clement S, 2004, DIABETES CARE, V27, P553, DOI 10.2337/diacare.27.2.553
  10. Dev R, 2018, ANN ONCOL, V29, P18, DOI 10.1093/annonc/mdx815
  11. Donihi Amy Calabrese, 2006, Endocr Pract, V12, P358
  12. Tamez-Perez HE, 2015, WORLD J DIABETES, V6, P1073, DOI 10.4239/wjd.v6.i8.1073
  13. Esguerra JLS, 2020, MOL METAB, V32, P160, DOI 10.1016/j.molmet.2019.12.012
  14. Fokkert MJ, 2017, BMJ OPEN DIAB RES CA, V5, DOI 10.1136/bmjdrc-2016-000320
  15. Fonseca VA, 2016, ENDOCR PRACT, V22, P1008, DOI 10.4158/EP161392.CS
  16. Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
  17. Healy SJ, 2017, ENDOCRINE, V56, P90, DOI 10.1007/s12020-016-1220-2
  18. Hiestand A, 2019, CURR DIABETES REP, V19, DOI 10.1007/s11892-019-1283-6
  19. Jian ZY, 2018, CELL MOL GASTROENTER, V6, P429, DOI 10.1016/j.jcmgh.2018.07.003
  20. Karlin NJ, 2012, ENDOCR PRACT, V18, P898, DOI 10.4158/EP12128.OR
  21. Katsuyama T, 2015, DIABETES RES CLIN PR, V108, P273, DOI 10.1016/j.diabres.2015.02.010
  22. Kim Y, 2014, DIABETES RES CLIN PR, V103, P437, DOI 10.1016/j.diabres.2013.11.026
  23. Lamar ZS, 2018, LEUKEMIA LYMPHOMA, V59, P1871, DOI 10.1080/10428194.2017.1410889
  24. Liu XX, 2014, ANN NUTR METAB, V65, P324, DOI 10.1159/000365892
  25. Lockhart CJ, 2011, CLIN SCI, V121, P129, DOI 10.1042/CS20100448
  26. Lyall MJ, 2018, DIABETIC MED, V35, P1508, DOI 10.1111/dme.13770
  27. Olczuk D, 2018, DIABETES METAB SYND, V12, P181, DOI 10.1016/j.dsx.2017.09.005
  28. Perez A, 2014, J DIABETES, V6, P9, DOI 10.1111/1753-0407.12090
  29. Pomposelli JJ, 1998, JPEN-PARENTER ENTER, V22, P77, DOI 10.1177/014860719802200277
  30. Rowbottom L, 2015, ANN PALLIAT MED, V4, P70, DOI 10.3978/j.issn.2224-5820.2015.04.07
  31. Suh S, 2017, ENDOCRINOL METAB, V32, P180, DOI 10.3803/EnM.2017.32.2.180
  32. Teuffel O, 2011, LEUKEMIA, V25, P1232, DOI 10.1038/leu.2011.84
  33. Umpierrez GE, 2002, J CLIN ENDOCR METAB, V87, P978, DOI 10.1210/jc.87.3.978
  34. Umpierrez GE, 2012, J CLIN ENDOCR METAB, V97, P16, DOI 10.1210/jc.2011-2098
  35. Vu K, 2012, CL LYMPH MYELOM LEUK, V12, P355, DOI 10.1016/j.clml.2012.05.004
  36. WALSH D, 1992, CLEV CLIN J MED, V59, P505, DOI 10.3949/ccjm.59.5.505
  37. Weiser MA, 2004, CANCER, V100, P1179, DOI 10.1002/cncr.20071

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/10
Artigos e Materiais de Revistas Científicas - LIM/31
Artigos e Materiais de Revistas Científicas - ODS/03